✦ LIBER ✦

Advanced breast cancer: A randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine

✍ Scribed by J. A. Green; A. J. Slater; I. R. Campbell; V. Kelly

Publisher: Springer US
Year: 1996
Tongue: English
Weight: 676 KB
Volume: 39
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01806182

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone combined to vincristine, cy

Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer

✍ R. Metz; M. Delgado; R. Keiling; P. Cappelaere; J. P. Armand; G. Prevot; J. L. M 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 301 KB

In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on

First-line combination chemotherapy with

First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer

✍ P. Periti; G. Robustelli Delia Cuna; F. Pannuti; T. Mazzei; P. Preti; A. Martoni 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 312 KB

In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3-4 weeks, for a maximum of 12 cycles. The over

Doxorubicin and CCNU with or without vin

Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer a randomized trial

✍ Rowan T. Chlebowski; Reginald Pugh; John M. Weiner; Jerome B. Block; Joseph R. B 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB 👁 2 views

A randomized trial of doxorubicin, mitox

A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study)

✍ John D. Cowan; C. Kent Osborne; James A. Neidhart; Daniel D. Hoff; John J. Const 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 295 KB

New agents with increased activity and/or reduced toxicity are needed for the treatment of advanced breast cancer. The anthracene derivatives mitoxantrone and bisantrene had significant activity and acceptable toxicity in phase II trials. In an ongoing phasc III trial we have now randomized 150 pati

Vincristine, doxorubicin, and cyclophosp

Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer. A randomized trial of the piedmont oncology association

✍ Hyman B. Muss; Frederick Richards II; Don V. Jackson; M. Robert Cooper; Douglas 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 538 KB

Vincristine, doxorubicin and mitomycin (

Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF)

✍ Sharon K. Shipp; Hyman B. Muss; Mary Alice Westrick; M. Robert Cooper; V. Jackso 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 383 KB

Thirty-six evaluable patients with advanced breast cancer who had failed prior CMF therapy [15 (42%) as adjuvant treatment and 21 (58%) for advanced disease] were treated with a combination of vincristine, doxorubicin, and mitomycin (VAM). There was one CR and 10 PR, giving a response rate of 31% (P